组蛋白去乙酰化酶抑制剂治疗非霍奇金淋巴瘤研究进展  

Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma

作　　者：陈馨蕊 宋腾[1] 张廷 王华庆[1] Chen Xinrui;Song Teng;Zhang Ting;Wang Huaqing(Cancer Diagnosis and Treatment Center,Tianjin People's Hospital,Tianjin Cancer Research Institute of Traditional Chinese and Western Medicine,Tianjin 300121,China)

机构地区：[1]天津市人民医院肿瘤诊治中心,天津市中西医结合肿瘤研究所,300121

出　　处：《白血病．淋巴瘤》2020年第9期573-576,共4页Journal of Leukemia & Lymphoma

摘　　要：目前针对复发难治性非霍奇金淋巴瘤(NHL),治疗方案较少且疗效有限。组蛋白去乙酰化酶抑制剂(HDACi)可以通过靶向抑制组蛋白去乙酰化酶(HDAC)活性,调控基因表达,从而发挥抗肿瘤作用。HDACi单药或联合其他抗肿瘤药物治疗复发难治NHL表现出较好的疗效。现就HDACi治疗NHL的进展进行综述。At present,there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma(NHL).Histone deacetylase inhibitors(HDACi)exert anti-tumor effects by inhibiting the activation of histone deacetylase(HDAC)and regulating gene expression.HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL.This article reviews the progress of HDACi in the treatment of NHL.

关 键 词：淋巴瘤 非霍奇金 蛋白激酶抑制剂 药物疗法 联合 

分 类 号：R733.1[医药卫生—肿瘤]